News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,437 Results
Type
Article (42732)
Company Profile (270)
Press Release (689419)
Multimedia
Podcasts (90)
Webinars (20)
Section
Business (206039)
Career Advice (2053)
Deals (35697)
Drug Delivery (124)
Drug Development (81810)
Employer Resources (173)
FDA (16542)
Job Trends (15028)
News (348509)
Policy (32878)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2654)
Academic (1)
Accelerated approval (44)
Adcomms (25)
Allergies (160)
Alliances (50131)
ALS (193)
Alzheimer's disease (1753)
Antibody-drug conjugate (ADC) (375)
Approvals (16858)
Artificial intelligence (616)
Autoimmune disease (228)
Automation (51)
Bankruptcy (363)
Best Places to Work (11687)
BIOSECURE Act (20)
Biosimilars (204)
Biotechnology (177)
Bladder cancer (178)
Brain cancer (65)
Breast cancer (692)
Cancer (5378)
Cardiovascular disease (448)
Career advice (1740)
Career pathing (40)
CAR-T (300)
CDC (54)
Celiac Disease (2)
Cell therapy (808)
Cervical cancer (43)
Clinical research (70445)
Collaboration (1920)
Company closure (4)
Compensation (1295)
Complete response letters (70)
COVID-19 (2756)
CRISPR (100)
C-suite (995)
Cystic fibrosis (149)
Data (7097)
Decentralized trials (3)
Denatured (29)
Depression (154)
Dermatology (61)
Diabetes (549)
Diagnostics (6987)
Digital health (53)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (302)
Drug pricing (195)
Drug shortages (30)
Duchenne muscular dystrophy (266)
Earnings (91262)
Editorial (61)
Employer branding (21)
Employer resources (152)
Events (119156)
Executive appointments (1040)
FDA (19992)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (31)
Funding (1638)
Gene editing (214)
Generative AI (54)
Gene therapy (657)
GLP-1 (1016)
Government (4720)
Grass and pollen (6)
Guidances (398)
Healthcare (19028)
HIV (74)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (275)
Immuno-oncology (81)
Indications (158)
Infectious disease (3072)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (131)
Intellectual property (277)
Interviews (317)
IPO (16710)
IRA (50)
Job creations (3662)
Job search strategy (1448)
JPM (58)
Kidney cancer (18)
Labor market (92)
Layoffs (555)
Leadership (36)
Legal (7962)
Liver cancer (98)
Longevity (28)
Lung cancer (722)
Lymphoma (406)
Machine learning (53)
Management (59)
Manufacturing (933)
MASH (177)
Medical device (13892)
Medtech (13969)
Mergers & acquisitions (20151)
Metabolic disorders (1411)
mRNA (177)
Multiple sclerosis (174)
NASH (17)
Neurodegenerative disease (384)
Neuropsychiatric disorders (97)
Neuroscience (3155)
Neurotech (1)
NextGen: Class of 2026 (6569)
Non-profit (4573)
Now hiring (74)
Obesity (665)
Opinion (282)
Ovarian cancer (187)
Pain (231)
Pancreatic cancer (258)
Parkinson's disease (341)
Partnered (33)
Patents (561)
Patient recruitment (597)
Peanut (60)
People (59722)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21983)
Phase 2 (31017)
Phase 3 (23072)
Pipeline (7227)
Policy (303)
Postmarket research (2572)
Preclinical (9408)
Press Release (65)
Prostate cancer (278)
Psychedelics (49)
Radiopharmaceuticals (309)
Rare diseases (1000)
Real estate (6006)
Recruiting (70)
Regulatory (25123)
Reports (54)
Research institute (2476)
Resumes & cover letters (358)
Rett syndrome (33)
RNA editing (17)
RSV (86)
Schizophrenia (164)
Series A (271)
Series B (203)
Service/supplier (11)
Sickle cell disease (107)
Special edition (22)
Spinal muscular atrophy (167)
Sponsored (45)
Startups (3670)
State (2)
Stomach cancer (18)
Supply chain (121)
Tariffs (86)
The Weekly (59)
Vaccines (1063)
Venture capital (98)
Weight loss (422)
Women's health (113)
Worklife (20)
Date
Today (117)
Last 7 days (549)
Last 30 days (2618)
Last 365 days (30157)
2026 (8347)
2025 (30355)
2024 (35386)
2023 (40269)
2022 (51390)
2021 (55965)
2020 (54358)
2019 (46833)
2018 (35229)
2017 (32378)
2016 (31794)
2015 (37877)
2014 (31559)
2013 (26732)
2012 (28903)
2011 (29571)
2010 (27635)
Location
Africa (750)
Alabama (91)
Alaska (7)
Arizona (332)
Arkansas (13)
Asia (39884)
Australia (6551)
California (12386)
Canada (3523)
China (1234)
Colorado (526)
Connecticut (528)
Delaware (370)
Europe (86815)
Florida (1864)
Georgia (396)
Hawaii (3)
Idaho (62)
Illinois (965)
India (82)
Indiana (562)
Iowa (22)
Japan (495)
Kansas (130)
Kentucky (45)
Louisiana (38)
Maine (73)
Maryland (1500)
Massachusetts (8855)
Michigan (347)
Minnesota (680)
Mississippi (6)
Missouri (141)
Montana (33)
Nebraska (29)
Nevada (136)
New Hampshire (82)
New Jersey (3287)
New Mexico (29)
New York (3267)
North Carolina (1572)
North Dakota (9)
Northern California (6118)
Ohio (371)
Oklahoma (22)
Oregon (42)
Pennsylvania (2497)
Puerto Rico (27)
Rhode Island (50)
South America (1122)
South Carolina (79)
South Dakota (1)
Southern California (4877)
Tennessee (200)
Texas (1960)
United States (43851)
Utah (371)
Vermont (1)
Virginia (293)
Washington D.C. (80)
Washington State (991)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
732,437 Results for "molecular templates inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Drug Development
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its programs.
March 4, 2024
·
9 min read
Business
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results for the fourth quarter and full year ended December 31, 2023.
March 29, 2024
·
13 min read
Business
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.
May 15, 2024
·
6 min read
Business
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2023.
November 13, 2023
·
12 min read
Press Releases
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 10, 2026
·
7 min read
Lone Star Bio
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
February 8, 2024
·
3 min read
Lone Star Bio
Molecular Templates to Participate in Upcoming November 2023 Investor Conferences
Molecular Templates, Inc. announced participation in the following upcoming investor conferences.
November 1, 2023
·
3 min read
Press Releases
Moolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seeds
April 7, 2026
·
4 min read
Business
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. today reported financial results and business updates for the second quarter of 2023.
August 10, 2023
·
16 min read
1 of 73,244
Next
